Cargando…
Preparation, Characterization, Pharmacokinetic, and Therapeutic Potential of Novel 6-Mercaptopurine-Loaded Oral Nanomedicines for Acute Lymphoblastic Leukemia
BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common hematologic malignancy in children. It requires a long and rigorous course of chemotherapy treatments. 6-Mercaptopurine (6-MP) is one of the primary drugs used in chemotherapy. Unfortunately, its efficacy has been limited due to its i...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886780/ https://www.ncbi.nlm.nih.gov/pubmed/33603372 http://dx.doi.org/10.2147/IJN.S290466 |
_version_ | 1783651869563813888 |
---|---|
author | Zou, Yaru Mei, Dong Yuan, Jinjie Han, Jiaqi Xu, Jiamin Sun, Ning He, Huan Yang, Changqing Zhao, Libo |
author_facet | Zou, Yaru Mei, Dong Yuan, Jinjie Han, Jiaqi Xu, Jiamin Sun, Ning He, Huan Yang, Changqing Zhao, Libo |
author_sort | Zou, Yaru |
collection | PubMed |
description | BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common hematologic malignancy in children. It requires a long and rigorous course of chemotherapy treatments. 6-Mercaptopurine (6-MP) is one of the primary drugs used in chemotherapy. Unfortunately, its efficacy has been limited due to its insolubility, poor bioavailability and serious adverse effects. To overcome these drawbacks, we constructed 6-mercaptopurine (6-MP)-loaded nanomedicines (6-MPNs) with biodegradable poly(lactide-co-glycolide) (PLGA) to enhance the anticancer efficacy of 6-MP. METHODS: We prepared the 6-MPNs using a double-emulsion solvent evaporation method, characterizing them for the physicochemical properties. We then investigated the plasma, intestinal region and other organs in Sprague Dawley (SD) rats for pharmacokinetics. Additionally, we evaluated its anticancer efficacy in vitro on the human T leukemia cell line Jurkat and in vivo on the ALL model mice. RESULTS: The 6-MPNs were spherical in shape with uniform particle size and high encapsulation efficiency. The in vitro release profile showed that 6-MPNs exhibited a burst release that a sustained release phase then followed. The apoptosis assay demonstrated that 6-MPNs could improve the in vitro cytotoxicity in Jurkat cells. Pharmacokinetics profiles revealed that 6-MPNs had improved oral bioavailability. Tissue distribution experiments indicated that 6-MPNs increased the duodenum absorption of 6-MP, at the same time having a low accumulation of the toxic metabolites of 6-MP. The in vivo pharmacodynamics study revealed that 6-MPNs could prolong the survival time of the ALL model mice. The prepared 6-MPNs, therefore, have superior properties in terms of anticancer efficacy against ALL with reduced systemic toxicity. CONCLUSION: Our nanomedicines provide a promising delivery strategy for 6-MP; they offer a simple preparation method and high significance for clinical translation. |
format | Online Article Text |
id | pubmed-7886780 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-78867802021-02-17 Preparation, Characterization, Pharmacokinetic, and Therapeutic Potential of Novel 6-Mercaptopurine-Loaded Oral Nanomedicines for Acute Lymphoblastic Leukemia Zou, Yaru Mei, Dong Yuan, Jinjie Han, Jiaqi Xu, Jiamin Sun, Ning He, Huan Yang, Changqing Zhao, Libo Int J Nanomedicine Original Research BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common hematologic malignancy in children. It requires a long and rigorous course of chemotherapy treatments. 6-Mercaptopurine (6-MP) is one of the primary drugs used in chemotherapy. Unfortunately, its efficacy has been limited due to its insolubility, poor bioavailability and serious adverse effects. To overcome these drawbacks, we constructed 6-mercaptopurine (6-MP)-loaded nanomedicines (6-MPNs) with biodegradable poly(lactide-co-glycolide) (PLGA) to enhance the anticancer efficacy of 6-MP. METHODS: We prepared the 6-MPNs using a double-emulsion solvent evaporation method, characterizing them for the physicochemical properties. We then investigated the plasma, intestinal region and other organs in Sprague Dawley (SD) rats for pharmacokinetics. Additionally, we evaluated its anticancer efficacy in vitro on the human T leukemia cell line Jurkat and in vivo on the ALL model mice. RESULTS: The 6-MPNs were spherical in shape with uniform particle size and high encapsulation efficiency. The in vitro release profile showed that 6-MPNs exhibited a burst release that a sustained release phase then followed. The apoptosis assay demonstrated that 6-MPNs could improve the in vitro cytotoxicity in Jurkat cells. Pharmacokinetics profiles revealed that 6-MPNs had improved oral bioavailability. Tissue distribution experiments indicated that 6-MPNs increased the duodenum absorption of 6-MP, at the same time having a low accumulation of the toxic metabolites of 6-MP. The in vivo pharmacodynamics study revealed that 6-MPNs could prolong the survival time of the ALL model mice. The prepared 6-MPNs, therefore, have superior properties in terms of anticancer efficacy against ALL with reduced systemic toxicity. CONCLUSION: Our nanomedicines provide a promising delivery strategy for 6-MP; they offer a simple preparation method and high significance for clinical translation. Dove 2021-02-12 /pmc/articles/PMC7886780/ /pubmed/33603372 http://dx.doi.org/10.2147/IJN.S290466 Text en © 2021 Zou et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Zou, Yaru Mei, Dong Yuan, Jinjie Han, Jiaqi Xu, Jiamin Sun, Ning He, Huan Yang, Changqing Zhao, Libo Preparation, Characterization, Pharmacokinetic, and Therapeutic Potential of Novel 6-Mercaptopurine-Loaded Oral Nanomedicines for Acute Lymphoblastic Leukemia |
title | Preparation, Characterization, Pharmacokinetic, and Therapeutic Potential of Novel 6-Mercaptopurine-Loaded Oral Nanomedicines for Acute Lymphoblastic Leukemia |
title_full | Preparation, Characterization, Pharmacokinetic, and Therapeutic Potential of Novel 6-Mercaptopurine-Loaded Oral Nanomedicines for Acute Lymphoblastic Leukemia |
title_fullStr | Preparation, Characterization, Pharmacokinetic, and Therapeutic Potential of Novel 6-Mercaptopurine-Loaded Oral Nanomedicines for Acute Lymphoblastic Leukemia |
title_full_unstemmed | Preparation, Characterization, Pharmacokinetic, and Therapeutic Potential of Novel 6-Mercaptopurine-Loaded Oral Nanomedicines for Acute Lymphoblastic Leukemia |
title_short | Preparation, Characterization, Pharmacokinetic, and Therapeutic Potential of Novel 6-Mercaptopurine-Loaded Oral Nanomedicines for Acute Lymphoblastic Leukemia |
title_sort | preparation, characterization, pharmacokinetic, and therapeutic potential of novel 6-mercaptopurine-loaded oral nanomedicines for acute lymphoblastic leukemia |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886780/ https://www.ncbi.nlm.nih.gov/pubmed/33603372 http://dx.doi.org/10.2147/IJN.S290466 |
work_keys_str_mv | AT zouyaru preparationcharacterizationpharmacokineticandtherapeuticpotentialofnovel6mercaptopurineloadedoralnanomedicinesforacutelymphoblasticleukemia AT meidong preparationcharacterizationpharmacokineticandtherapeuticpotentialofnovel6mercaptopurineloadedoralnanomedicinesforacutelymphoblasticleukemia AT yuanjinjie preparationcharacterizationpharmacokineticandtherapeuticpotentialofnovel6mercaptopurineloadedoralnanomedicinesforacutelymphoblasticleukemia AT hanjiaqi preparationcharacterizationpharmacokineticandtherapeuticpotentialofnovel6mercaptopurineloadedoralnanomedicinesforacutelymphoblasticleukemia AT xujiamin preparationcharacterizationpharmacokineticandtherapeuticpotentialofnovel6mercaptopurineloadedoralnanomedicinesforacutelymphoblasticleukemia AT sunning preparationcharacterizationpharmacokineticandtherapeuticpotentialofnovel6mercaptopurineloadedoralnanomedicinesforacutelymphoblasticleukemia AT hehuan preparationcharacterizationpharmacokineticandtherapeuticpotentialofnovel6mercaptopurineloadedoralnanomedicinesforacutelymphoblasticleukemia AT yangchangqing preparationcharacterizationpharmacokineticandtherapeuticpotentialofnovel6mercaptopurineloadedoralnanomedicinesforacutelymphoblasticleukemia AT zhaolibo preparationcharacterizationpharmacokineticandtherapeuticpotentialofnovel6mercaptopurineloadedoralnanomedicinesforacutelymphoblasticleukemia |